Industry News

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for Xenpozyme  (olipudase alfa) for the treatment of adult and pediatric patients with non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD), a rare, progressive, and potentially life-threatening genetic disease.

Pharma Giant Pfizer recalls blood pressure medicines, brand name as Accuretic from the US market over presence of cancer causing impurities. Accuretic is a combination of quinapril HCl and hydrochlorothiazide.

Abbott received permission from the Subject Expert Committee to market a fixed dose combination (FDC) of Lidocaine and Diltiazem, after detailed deliberation by committee.

Abbott has presented a Phase III clinical trial report before the committee and after detailed deliberation, the committee recommended grant of permission for manufacturing and marketing of the proposed FDC.

Indoco Remedies Ltd. announces final approval from the United States Food and Drug Administration (USFDA) for Lacosamide Tablets USP 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat Tablets of UCB, Inc.

Lacosamide Tablets are indicated for the prevention and control of seizures. It is an anticonvulsant / antiepileptic drug.

Novavax, Inc a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the worlds largest vaccine manufacturer by volume, announced that the Drugs Controller General of India has granted emergency use authorization (EUA) for Novavax protein-based COVID-19 vaccine for adolescents aged ≥12 to <18 years in India.

Bharat Biotech has entered into a partnership with Biofabri, a Spanish biopharmaceutical firm, for the development, manufacturing and marketing of a new tuberculosis vaccine. This partnership will guarantee the supply of TB vaccines in more than 70 countries especially in Southeast Asia, and sub-Saharan Africa with a high TB incidence.

Granules India ltd has received a license from Medicines Patent Pool (MPP) to manufacture and market generic versions of Pfizer’s oral treatment nirmatrelvir which will be copackaged with ritonavir for treatment of COVID-19. The licenses are applicable for both active pharmaceutical ingredients (API) and finished products, in tablet form, of nirmatrelvir; ritonavir.

Granules India Limited, announced that Granules Pharmaceuticals, Inc. (GPI), a wholly-owned foreign subsidiary of the company, located in Chantilly, Virginia, USA received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA).

The GPI facility was inspected by the US FDA from 24th to 28th January 2022 for two of its product applications filed. There were three minor observations during the inspection and GPI had addressed the observations in the stipulated time period.

Indian pharmaceutical companies may replace western manufacturers leaving the Russian market, Russian envoy to India Denis Alipov said.

"The withdrawal of many Western companies from the Russian market and those niches that have been vacated may actually be occupied by Indian companies in many industries, in particular, in pharmaceuticals," Alipov told the Rossiya 24 broadcaster, as quoted by Sputnik news agency.